CClinicalTrials.gg
TerminatedNCT06247176ASD_VR_REUpdated May 29, 2026Results posted

Sensory Habituation in Autism Spectrum Disorders

An interventional study of Sensory Habituation Protocol in Autism Spectrum Disorder, Autism and Sensory Processing Disorder, sponsored by University of Nebraska. Terminated at 1 site in United States. Open to participants aged 7 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by University of Nebraska · Not applicable, Interventional, and Basic science

Why this study was terminated
PI no longer at institution.
Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Non-randomized
Ages
7 Years to 18 Years
Sex
All
01

Study summary

Autism spectrum disorder (ASD) is one of the most common developmental disabilities and often people with ASD have sensory processing disorders. These sensory processing disorders are often associated with problem behaviors and, more recently, have been connected to anxiety disorders in people with ASD. While it has been suggested that sensory processing responses in ASD could be malleable, current treatment strategies for sensory processing disorders in ASD have inconsistent results or lack large-sample sized data. This investigation will explore changes in neurophysiological activity in people with ASD and neurotypical peers after they are exposed to an unpleasant visual stimulus through a virtual reality systematic desensitization protocol. 30 people with ASD and 30 neurotypical people between the ages 7 - 35 will be recruited. The study have, 1) a practice magnetic resonance imaging (MRI) visit with questionnaires, 2) a per-exposure MRI with structural and functional MRI collections, 3) a virtual reality systematic desensitization session where we will record the participant's physiological response using an Emotibit device, and 4) a post-exposure MRI session with structural and functional MRI collections. This investigation aims to quantify changes in neurophysiological responses in order to determine the effect of systematic desensitization.

Read the detailed description

Autism Spectrum Disorder (ASD) is one of the most common developmental disabilities, with an estimated 1 in 54 children receiving a diagnosis. The total economic burden of ASD in the United States is estimated to be $268 billion and will increase to $461 billion by 2025. People with ASD have deficiencies in social relationships and communications and an increased rate of anxiety disorders, with some estimates suggesting 84% of people with ASD have anxiety. This anxiety can lead to an individual with ASD to exhibit avoidant behavior, which can include exclusion from activities to escalated behaviors that could be self-injurious or harmful to others. These avoidant behaviors can make participation in activities of daily living challenging for people with ASD, as the avoidant behavior is often considered socially-unacceptable behavior. While there has been increasing interest in anxiety in ASD, there is still a major knowledge gap in understanding how sensory processing disorders play a role in anxiety and if this can be treated.

Sensory Processing in ASD: Sensory processing disorders were added to ASD diagnosis in The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition in 2013. Since then, there has been little research into the role that sensory processing disorders plays in the anxiety of people with ASD. Functional magnetic resonance imaging (fMRI) studies have demonstrated that people with ASD have greater brain activity in relevant sensory areas, the amygdala, and the orbital frontal cortex when exposed to combinations of unpleasant auditory, tactile, or visual stimuli. Further, people with ASD have a reduced ability to habituate to the same unpleasant stimuli in the relevant sensory cortices and amygdala, differences in the changes of brain activity in the orbital-frontal cortex, and differences in functional connectivity between the amygdala and orbital-frontal cortex. These brain responses have also been connected with physiological responses in children with ASD, as those with greater skin conductivity having reduced neural response in the orbital-frontal cortex and heart rate being positively correlated with activity in the inferior and medial frontal gyrus.

Even though the neurophysiological evidence supports sensory processing differences in ASD, current treatment strategies are sparse and the results are often inconsistent. The most successful paradigm is exposure therapy through systematic desensitization, which has been used in both ASD and people with anxiety. While multisensory integration skills may be malleable, it has been suggested that exposure therapy may not be an effective long-term strategy, as the clinical team cannot perform exposure to every stimulus in every environment. With this in mind, new therapeutic techniques need to be designed to enable personalization of exposure experiences.

Virtual Reality for ASD: One emerging technique that could enable quick personalization of unpleasant stimulus and environments is virtual reality (VR). Therapeutic VR software has shown to be an effective platform for skill training, mainly focusing on behavioral skills in social or educational environments. Two investigations demonstrated changes in neural activity after participating in VR social cognition training. However, the effects of using VR as a sensory exposure platform on the physiological response to unpleasant stimuli has not been explored.

Purpose The research objectives of this application are to quantify the neurophysiological changes that occur after participating in a virtual reality systematic desensitization protocol. The following aims will be achieved the top physiological recording devices for ASD to collect physiological responses, front-line virtual reality systems to provide automated desensitization exposure therapy, and University of Nebraska Medical Center's research MRI system. 30 people with ASD and 30 neurotypical peers will be recruited to utilize this software. This proposal will be the first step in developing evidence-based therapies aimed at addressing sensory processing differences in ASD.

02

Conditions studied

  • Autism Spectrum Disorder
  • Autism
  • Sensory Processing Disorder
  • Sensory Over-Responsivity

Keywords

  • Autism
  • Autism Spectrum Disorder
  • Virtual Reality
  • Sensory Sensitivity
  • Sensory Hyper-reactivity
  • Sensory Processing
  • Sensory Over-Responsivity
03

In context

Autism Spectrum Disorder

1,727 studies on the registry are indexed under Autism Spectrum Disorder; 504 are open to participants now.

This study's enrollment of 1 is below the median of 52 across 1,371 interventional studies indexed under Autism Spectrum Disorder.

Browse Autism Spectrum Disorder studies →

Lead sponsor

University of Nebraska is the lead sponsor of 473 studies on the registry; 66 are open to participants now.

Of its 75 completed or terminated interventional studies of FDA-regulated products, 46 (61%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • For our patient population

    1. people with a diagnosis of autism spectrum disorder
    2. people who have sensory over-responsivity
    3. can wear a VR headset for up to 20 minutes
    4. can understand and follow directions

For neurotypical participants

  1. can wear a VR headset for up to 20 minutes
  2. can understand and follow directions

Exclusion criteria

Exclusion Criteria:

  • 1) if you have any known visual impairment that will make it difficult to watch an object in a VR headset 2) inability to wear a VR headset 3) a history of seizures 4) A subject with orthodontic braces or metallic implants, such as prostheses, shrapnel, or aneurysm clips, or persons with electronic implants, such as cardiac pacemakers. The magnetic field generated by the MRI machine can cause a displacement or malfunctioning of these devices; 5) A subject who is claustrophobic, unable to stay still in the scanner for 40 minutes, or unable to be in the MRI scanner room alone;
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Autism Spectrum Disorder Habituation Group

    This will be the group of subjects with Autism and sensory over-responsivity. This group will go through a mock-MRI, a pre-habituation MRI, the habituation protocol in virtual reality, and a post-habituation MRI.

    Behavioral: Sensory Habituation Protocol

  • Active comparator
    Neurotypical Habitation Group

    This will be the group of subjects who are neurotypical peers. This group will go through a mock-MRI, a pre-habituation MRI, the habituation protocol in virtual reality, and a post-habituation MRI.

    Behavioral: Sensory Habituation Protocol

Interventions

  • BehavioralSensory Habituation Protocol

    The first session continues with the Mock MRI, which lasts 10 minutes. Participant's comfort level in VR will be evaluated. At the pre-exposure visit, participants complete an MRI scan on a 3 Tesla MRI, which takes approximately 1 hour \& 15 minutes. It consists of structural \& functional MRI scans. Structural scans require the participant to stay still with eyes closed. Functional scans will require the participant to lie with eyes closed or watch and listen to sensory stimulation. VR exposure will occur across 3 1-hour sessions at most. Participants will be asked to complete a sensory habituation protocol, in which they will watch and listen to sensory stimuli in VR for an increasing amount of time. Between the sensory stimuli, the participant will watch a self-selected video. Finally, the subject will be asked to do a post-exposure MRI visit, which is the same as the pre-exposure visit.

    Also known as: Repeated Exposure

06

What researchers measure

Primary outcomes

  1. Changes in Neural Response to the Sensory Stimulation

    This will be the change in the bold response as measured by the fMRI scan.

    Time frame: There are two 1 hour sessions in which the bold response will be measured. The first time point will be during visit 2 of the study. The second time point will be the final visit of the study.

Secondary outcomes

  1. Galvanic Skin Response as Measured by a Physiological Recording Devices, Either an Emotibit or the MRI Scanner

    Galvanic skin response is a measure of how sweaty the skin is and can be used as a measure of the body's stress. We will look at this before during and after the habituation protocol to measure how the body adapts to the sensory stimulation.

    Time frame: Galvanic skin response will be measured at 3 - 5 time points, ranging from 1 hour and 30 minutes to 3 hours and 30 minutes of data. 15 minutes will be measured at the 2nd and last visit. 1 hour will be collected at each VR visit.

  2. Changes in Skin Temperature After Going Through a Sensory Habituation Protocol, Measured by an Emotibit

    This will look at the change in the skins temperature before, during, and after the sensory habituation protocol. This is a measure of the body's response to a stressor.

    Time frame: Skin temperature will be measured at 1 - 3 time points, ranging from 1 hour to 3 hours of data. 1 hour will be collected at each VR visit.

  3. Heart Rate Changes as Measured by a Physiological Recording Devices, Either an Emotibit or the MRI Scanner

    Changes in heart rate can give an indication of stress and habituation. This will be recorded before, during, and after the habituation protocol to assess how the body reacts.

    Time frame: Heart rate will be measured at 3 - 5 time points, ranging from 1 hour and 30 minutes to 3 hours and 30 minutes of data. 15 minutes will be measured at the 2nd and last visit. 1 hour will be collected at each VR visit.

07

Results

Posted May 29, 2026

Participant flow

Participant flow — Overall Study
MilestoneAutism Spectrum Disorder Habituation GroupNeurotypical Habitation Group
Started10
Completed10
Not completed00

Outcome measures

PrimaryChanges in Neural Response to the Sensory Stimulation

This will be the change in the bold response as measured by the fMRI scan.

Time frame:
There are two 1 hour sessions in which the bold response will be measured. The first time point will be during visit 2 of the study. The second time point will be the final visit of the study.
Reported as:
Mean · BOLD Response

No measurements were reported for this outcome.

SecondaryGalvanic Skin Response as Measured by a Physiological Recording Devices, Either an Emotibit or the MRI Scanner

Galvanic skin response is a measure of how sweaty the skin is and can be used as a measure of the body's stress. We will look at this before during and after the habituation protocol to measure how the body adapts to the sensory stimulation.

Time frame:
Galvanic skin response will be measured at 3 - 5 time points, ranging from 1 hour and 30 minutes to 3 hours and 30 minutes of data. 15 minutes will be measured at the 2nd and last visit. 1 hour will be collected at each VR visit.
Reported as:
Mean · uS

No measurements were reported for this outcome.

SecondaryChanges in Skin Temperature After Going Through a Sensory Habituation Protocol, Measured by an Emotibit

This will look at the change in the skins temperature before, during, and after the sensory habituation protocol. This is a measure of the body's response to a stressor.

Time frame:
Skin temperature will be measured at 1 - 3 time points, ranging from 1 hour to 3 hours of data. 1 hour will be collected at each VR visit.
Reported as:
Mean · F

No measurements were reported for this outcome.

SecondaryHeart Rate Changes as Measured by a Physiological Recording Devices, Either an Emotibit or the MRI Scanner

Changes in heart rate can give an indication of stress and habituation. This will be recorded before, during, and after the habituation protocol to assess how the body reacts.

Time frame:
Heart rate will be measured at 3 - 5 time points, ranging from 1 hour and 30 minutes to 3 hours and 30 minutes of data. 15 minutes will be measured at the 2nd and last visit. 1 hour will be collected at each VR visit.
Reported as:
Mean · BPM

No measurements were reported for this outcome.

Adverse events

Collected over From enrollment until the end of follow-up, approximately 4 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Autism Spectrum Disorder Habituation Group0/1 (0%)0/1 (0%)0/1 (0%)
Neurotypical Habitation Group———

Baseline characteristics

Project was terminated before full scale analysis was performed.

Age, Categorical
Age, Categorical(Participants)Autism Spectrum Disorder Habituation GroupNeurotypical Habitation GroupTotal
<=18 years101
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Autism Spectrum Disorder Habituation GroupNeurotypical Habitation GroupTotal
Female000
Male101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Autism Spectrum Disorder Habituation GroupNeurotypical Habitation GroupTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101
More than one race000
Unknown or Not Reported000
Handedness
Handedness(Participants)Autism Spectrum Disorder Habituation GroupNeurotypical Habitation GroupTotal
Right Handed1—1
Left Handed0—0
08

Study locations

1 site
  • University of Nebraska Medical Center, Munroe-Meyer Insitute
    Omaha, Nebraska 68106, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · May 22, 2026

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — De-identified MRI scans and physiological responses will be made available after completion of the study.

Supporting information: Study protocol

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06247176
Lead sponsor
University of Nebraska
Responsible party
Sponsor
First posted
Feb 7, 2024
Start date
Jan 8, 2024
Primary completion
Oct 7, 2024
Completion
Oct 7, 2024
Results posted
May 29, 2026
Last update
May 29, 2026

Study contacts

James E Gehringer, PhD
principal investigator · University of Nebraska

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion